Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH1 | Q92800 | 12/20 | 0.70 |
| ▸ | EZH2 | Q15910 | 11/20 | 0.70 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.68 |
| ▸ | EED | O75530 | 1/20 | 0.68 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.68 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.68 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.68 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.68 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351394 | 0.86 | EZH1 (0.92) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL16767552 | 0.86 | EZH1 (0.92) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL18864299 | 0.84 | EZH1 (0.64) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL23863677 | 0.83 | EZH2 (0.76) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL12180659 | 0.81 | EZH1 (1.00) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL2591377 | 0.80 | EZH1 (1.00) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL30459645 | 0.80 | EZH1 (1.00) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL24227145 | 0.80 | EZH2 (0.58) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL2594776 | 0.79 | EZH1 (0.87) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL21284988 | 0.78 | EZH1 (0.88) | EZH1EZH2PRMT3EEDRBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10987353-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190134025-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134025-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | CARM1, EZH2, PRMT1 | EZH1 17/4885EZH2 2/4885PRMT3 4/4885 |
| US-10987353-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs | CARM1, EZH2, PRMT1 | EZH1 17/4885EZH2 2/4885PRMT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.